Home Our Team Faculty Michael Fisher, MD Profile

Michael Fisher, MD

Michael  Fisher, MD

Attending physician

Assistant professor of Pediatrics, University of Pennsylvania School of Medicine

Contact Michael Fisher, MD

Resume

Specialties and Services

Education

Harvard Medical School (MD), Cambridge, Mass.

Amherst College, Amherst, MA (BA, psychology)

Internship

Children's Hospital Boston, Mass.

Residency

Children's Hospital Boston, Mass.

Fellowship

Hematology/Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pa. Neuro-Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pa.

Board Certification

American Board of Pediatrics
American Board of Pediatrics/Pediatric Hematology-Oncology

Year Appointed

2002

Special Interests

Management of brain tumors
Neurofibromatosis (NF) and NF-related tumors
Brain tumor survivorship
Imaging of plexiform neurofibromas and brain tumors

Extended Bio

Specialties and Services

Education

Harvard Medical School (MD), Cambridge, Mass.

Amherst College, Amherst, MA (BA, psychology)

Internship

Children's Hospital Boston, Mass.

Residency

Children's Hospital Boston, Mass.

Fellowship

Hematology/Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pa. Neuro-Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pa.

Board Certification

American Board of Pediatrics
American Board of Pediatrics/Pediatric Hematology-Oncology

Year Appointed

2002

Special Interests

Management of brain tumors
Neurofibromatosis (NF) and NF-related tumors
Brain tumor survivorship
Imaging of plexiform neurofibromas and brain tumors

Publications

Original Papers

Palmer SL, Hassall T, Evankovich K, Mabbott DJ, Bonner M, Deluca C, Cohn R, Fisher MJ, Morris EB, Broniscer A, Gajjar A. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol. 2010 Aug 16.

Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B. Objective response of multiply recurrent pediatric low-grade gliomas to bevacizumab and irinotecan. Pediatric Blood & Cancer, 52:791–795, 2009.

Chi SN, Zimmerman MA, Yao X, Fletcher W, Cohen K, Burger P, Biegel J, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley P, Bowers D, Bendel A, Rubin J, Turner CD, Marcus K, Goumnerova L, Roberts C, Ullrich N, Chordas C, Kieran MW. Intensive Multi-Modality Treatment for Children with Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor. J Clin Oncol, 27(3):385-9, 2009.

Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, Cnaan A, Zhuang H, Phillips PC, Alavi A. The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol, 87:165-171, 2008.

Shu, H-KG, Sall WF, Maity A, Tochner ZA, Janss AJ, Belasco JB, Rorke-Adams LB, Phillips PC, Sutton LN, Fisher MJ. Childhood intracranial ependymoma: 20 year experience from a single institution. Cancer, 110(2):432-441, 2007.

Armstrong GT, Localio AR, Feygin T, Bilaniuk L, Phillips PC, Fisher MJ, Strom BL, Zimmerman R. Defining Optic Nerve Tortuosity. AJNR, 28:666-671, 2007.

Gururangan S, Fisher MJ, Allen JC, Herndon II JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neurooncology, 9(2): 161-168, 2007.

Gardner S, Fisher M, Belasco J, Phillips P, Finlay J. Phase I dose escalation of temozolomide with thiotepa and carboplatin with autologous hematopoietic cell reinfusion in patients with recurrent/refractory malignant brain tumors. 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. Journal of Clinical Oncology, 25(18S): 90s, 2007.